Current Opinion in Hematology最新文献_第10页

Editorial: Molecular advances make the day in myeloid diseases. 社论：髓系疾病的分子研究取得进展

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-03-01 DOI: 10.1097/MOH.0000000000000751

Stephanie Halene

引用次数: 0

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication. 骨髓增生异常肿瘤在疾病分类和预后中的分子景观。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-03-01 DOI: 10.1097/MOH.0000000000000752

Giulia Maggioni, Matteo G Della Porta

{"title":"Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.","authors":"Giulia Maggioni, Matteo G Della Porta","doi":"10.1097/MOH.0000000000000752","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000752","url":null,"abstract":"Purpose of review: The aim of this review is to provide a complete perspective of the evidence that led to the three recent new landmarks of myelodysplastic syndromes (MDS) definition and prognostication: the WHO 2022 and International Consensus Classification (ICC) 2022 classification and the Molecular Intermational Prognostic Scoring System (IPSS-M) score.Recent findings: The molecular founding lesions of MDS are strongly linked with disease phenotype and prognosis, therefore the genetic assessment have become part of MDS classifications and prognostication.Summary: The WHO 2022 now recognizes the class 'MDS with defining genetic abnormalities'. It includes 'MDS with SF3B1 mutation', and 'MDS with biallelic TP53 inactivation'. The ICC 2022 further introduces the category 'MDS/acute myeloid leukemia (AML)' emphasizing the biological continuum existing between the diseases, with the aim to expand therapeutic possibilities for MDS patients with more than 10% of blasts; it further identifies 9 MDS-funding lesions, defying the 'MDS/AML with myelodysplasia-related gene mutations' class. In recent years, many efforts have been done in order to specify and weight the role of mutations in disease prognostication; the IPSS-M proposed in 2022 finally integrates the molecular profile of the disease with the clinical and cytogenetic data, providing a better prognostication at patient level compared to IPSS-R.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 2","pages":"30-37"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10633098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. 多发性红细胞症中的拟肝素：解决缺铁与红细胞增多症的矛盾。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-03-01 Epub Date: 2022-12-29 DOI: 10.1097/MOH.0000000000000747

Shivani Handa, Yelena Ginzburg, Ronald Hoffman, Marina Kremyanskaya

{"title":"Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.","authors":"Shivani Handa, Yelena Ginzburg, Ronald Hoffman, Marina Kremyanskaya","doi":"10.1097/MOH.0000000000000747","DOIUrl":"10.1097/MOH.0000000000000747","url":null,"abstract":"Purpose of review: Development of hepcidin therapeutics has been a ground-breaking discovery in restoring iron homeostasis in several haematological disorders. The hepcidin mimetic, rusfertide, is in late-stage clinical development for treating polycythemia vera patients with a global phase 3 trial [NCT05210790] currently underway. Rusfertide serves as the first possible noncytoreductive therapeutic option to maintain haematocrit control and avoid phlebotomy in polycythemia vera patients. In this comprehensive review, we discuss the pathobiology of dysregulated iron metabolism in polycythemia vera, provide the rationale for targeting the hepcidin-ferroportin axis and elaborate on the preclinical and clinical trial evidence supporting the role of hepcidin mimetics in polycythemia vera.Recent findings: Recently, updated results from two phase 2 clinical trials [NCT04057040 & NCT04767802] of rusfertide (PTG300) demonstrate that the drug is highly effective in eliminating the need for therapeutic phlebotomies, normalizing haematological parameters, repleting iron stores and relieving constitutional symptoms in patients with polycythemia vera. In light of these findings, additional hepcidin mimetic agents are also being evaluated in polycythemia vera patients.Summary: Hepcidin agonists essentially serve as a 'chemical phlebotomy' and are poised to vastly improve the quality of life for phlebotomy requiring polycythemia vera patients.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 2","pages":"45-52"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10642874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Introductions. 编辑介绍。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-03-01 DOI: 10.1097/MOH.0000000000000757

引用次数: 0

Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. 骨髓增生异常综合征和急性髓性白血病的新型免疫导向疗法。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2023-03-01 Epub Date: 2022-12-23 DOI: 10.1097/MOH.0000000000000749

Andrew M Brunner

{"title":"Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.","authors":"Andrew M Brunner","doi":"10.1097/MOH.0000000000000749","DOIUrl":"10.1097/MOH.0000000000000749","url":null,"abstract":"Purpose of review: Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody-drug conjugates, and cellular therapies.Recent findings: This review outlines updates in the preclinical rationale for immune directed therapies in MDS and AML, as well as recent clinical trials exploring these therapies. This manuscript summarizes the development of therapies targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and CD47, which are being evaluated in late phase studies in MDS and AML. It also reviews the landscape of other immune based therapies including antibody-drug conjugates, chimeric antigen receptor-T cells, bispecific antibodies, and tumor vaccines.Summary: The treatment landscape in MDS and AML is rapidly changing; with a goal of improving the quality and duration of responses, a number of immune based therapies are under investigation. This review outlines recent advances with these therapies as well as some of the challenges that remain to incorporate them into leukemia care.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 2","pages":"38-44"},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10616031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Old age: the crown of life, our play's last act. Question and answers on older patients undergoing allogeneic hematopoietic cell transplantation. 老年:人生的王冠，我们戏剧的最后一幕。老年患者异基因造血细胞移植的问题与解答。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-01-01 DOI: 10.1097/MOH.0000000000000743

Enrico Maffini, Moreno Festuccia, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafè, Mario Arpinati, Francesca Bonifazi

{"title":"Old age: the crown of life, our play's last act. Question and answers on older patients undergoing allogeneic hematopoietic cell transplantation.","authors":"Enrico Maffini, Moreno Festuccia, Margherita Ursi, Francesco Barbato, Michele Dicataldo, Marcello Roberto, Elena Campanini, Elisa Dan, Francesco De Felice, Serena De Matteis, Gianluca Storci, Massimiliano Bonafè, Mario Arpinati, Francesca Bonifazi","doi":"10.1097/MOH.0000000000000743","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000743","url":null,"abstract":"Purpose of review: Several studies showed that age alone should not be used as an arbitrary parameter to exclude patients from allogeneic hematopoietic cell transplantation (HCT). The accessibility to allogeneic HCT programs for older patients with hematological diseases is growing up constantly. The Center for International Blood and Marrow Transplant Research has recently shown that over 30% of allogeneic HCT recipients are at least 60 years old and that nearly 4% are aged 70 or more. Historically, the use of allogeneic HCT among elderly patients has been limited by age restrictions, reflecting physicians' concerns regarding prohibitive transplant-related mortality and HCT-associated morbidity.Recent findings: The introduction of reduced intensity/toxicity conditioning regimens has allowed transplant Centers to carry out allogeneic HCT on patients previously considered not ideal candidates. The integration of specific risk scores could lead to better capture mental and physical frailties of older patients. Older adults less frequently have available medically fit siblings, able to donate, so, unrelated donors, familial haploidentical donors or umbilical cord blood grafts could potentially abrogate such a difficulty, allowing the curative potential of allogeneic HCT.Summary: The appropriate assessing of allogeneic HCT feasibility for elderly patients should be the resonate application of different clinical and biological principles.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 1","pages":"14-21"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10777132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

N6-methyladenosine in hematological malignancies: a concise review. n6 -甲基腺苷在血液系统恶性肿瘤中的作用:简明综述。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-01-01 DOI: 10.1097/MOH.0000000000000741

Wan-Jie Wang, Ting-Ting Xu, Jing Bao

{"title":"N6-methyladenosine in hematological malignancies: a concise review.","authors":"Wan-Jie Wang, Ting-Ting Xu, Jing Bao","doi":"10.1097/MOH.0000000000000741","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000741","url":null,"abstract":"Purpose of review: Hematological malignancies are a kind of systemic cancers mostly related to abnormal differentiation of blood stem cells. Because of the poor prognosis, chemotherapy resistance and common recurrence, new mechanisms and treatment therapies are looking forward to be discovered.Recent findings: Over the years, epigenetic abnormalities have been known to act a key part in occurrence and development of hematological tumors. In the internal modifications on long noncoding eukaryotic mRNA, there is a common type called N6-methyladenosine that can change the expression of target genes and participate in the translation, degradation and splicing of mRNA. M6A is related to a wealth of cancers, such as HNRNPA2B1's elevation in multiple myeloma, METTLE3's elevation in acute myeloid leukemia and lung cancer. Immune cells, playing a significant role in hematological cancers, can also be regulated by m6A.Summary: In the review, we summarized the recent progress on hematological malignancies associating with m6A and immune cells, which may offer a new road for the treatment of them.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 1","pages":"4-13"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10833832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and opportunities in shared care for international patients treated with cellular therapy for nonmalignant disease. 国际非恶性疾病细胞治疗患者共享护理的挑战和机遇。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-01-01 DOI: 10.1097/MOH.0000000000000742

Syeda A Mina, Ibrahim N Muhsen, Shahrukh K Hashmi

引用次数: 1

Editorial introduction. 编辑介绍。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-01-01 DOI: 10.1097/MOH.0000000000000744

引用次数: 0

Haematopoietic stem cell quiescence exposed using mitochondrial membrane potential. 利用线粒体膜电位暴露的造血干细胞静止。

IF 3.2 3区医学

Current Opinion in Hematology Pub Date : 2023-01-01 Epub Date: 2022-11-24 DOI: 10.1097/MOH.0000000000000746

Saghi Ghaffari

{"title":"Haematopoietic stem cell quiescence exposed using mitochondrial membrane potential.","authors":"Saghi Ghaffari","doi":"10.1097/MOH.0000000000000746","DOIUrl":"10.1097/MOH.0000000000000746","url":null,"abstract":"Purpose of review: Quiescence is a fundamental property of haematopoietic stem cells (HSCs). Despite the importance of quiescence in predicting the potency of HSCs, tools that measure routinely the degree of quiescence or select for quiescent HSCs have been lacking. This Commentary discusses recent findings that address this fundamental gap in the HSC toolbox.Recent findings: Highly purified, phenotypically-defined HSCs are heterogeneous in their mitochondrial membrane potential (MMP). The lowest MMP subsets are enriched in greatly quiescent HSCs with the highest potency within the purified HSC population. MMP provides an intrinsic probe to select HSC subsets with unique cell cycle properties and distinct stem cell potential. Using this approach, new and unanticipated metabolic properties of quiescent HSCs' exit have been discovered. This methodology may improve the mechanistic understanding, of HSCs' exit from and entry to, quiescence.Summary: Selecting HSCs using MMP is likely to lead to discoveries of new HSC properties, may improve the ex vivo maintenance of HSCs and has implications for the clinic, including for improving HSC transplantations.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"30 1","pages":"1-3"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9331411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1